BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

910 related articles for article (PubMed ID: 27859263)

  • 1. Post-chemotherapy retroperitoneal teratoma in nonseminomatous germ cell tumors: Do predictive factors exist? Results from a national multicenter study.
    Dusaud M; Malavaud B; Bayoud Y; Sebe P; Hoepffner JL; Salomon L; Houlgatte A; Pignot G; Rigaud J; Fléchon A; Pfister C; Rouprêt M; Soulié M; Méjean A; Durand X
    J Surg Oncol; 2016 Dec; 114(8):992-996. PubMed ID: 27859263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical outcome of postchemotherapy retroperitoneal lymph node dissection and predicting retroperitoneal histology in advanced nonseminomatous germ cell tumours of the testis].
    Li XD; Guo SJ; Chen SL; Liu ZF; Dong P; Zhang ZL; Jiang LJ; Yao K; Li YH; Han H; Qin ZK; Liu ZW; Zhou FJ
    Zhonghua Wai Ke Za Zhi; 2017 Aug; 55(8):603-607. PubMed ID: 28789511
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical Outcome of Retroperitoneal Lymph Node Dissection after Chemotherapy in Patients with Pure Embryonal Carcinoma in the Orchiectomy Specimen.
    Dowling CM; Assel M; Musser JE; Meeks JJ; Sjoberg DD; Bosl G; Motzer R; Bajorin D; Feldman D; Carver BS; Sheinfeld J
    Urology; 2018 Apr; 114():133-138. PubMed ID: 29410311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term oncological outcome after post-chemotherapy retroperitoneal lymph node dissection in men with metastatic nonseminomatous germ cell tumour.
    Fléchon A; Tavernier E; Boyle H; Meeus P; Rivoire M; Droz JP
    BJU Int; 2010 Sep; 106(6):779-85. PubMed ID: 20089110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient selection for retroperitoneal lymph node dissection after chemotherapy for nonseminomatous germ cell tumors.
    Herr HW; Toner GC; Geller NL; Bosl GJ
    Eur Urol; 1991; 19(1):1-5. PubMed ID: 1848821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy of modified retroperitoneal lymph node dissection for testicular nonseminomatous germ cell tumors].
    Liu ZW; Zhou FJ; Han H; Qin ZK; Yu SL; Li YH; Ye YL; Teng XY
    Ai Zheng; 2008 Dec; 27(12):1302-6. PubMed ID: 19079998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection.
    Carver BS; Shayegan B; Eggener S; Stasi J; Motzer RJ; Bosl GJ; Sheinfeld J
    J Clin Oncol; 2007 Oct; 25(28):4365-9. PubMed ID: 17906201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary vs. post-chemotherapy retroperitoneal lymph node dissection (RPLND) in patients with presence of teratoma at orchiectomy.
    Williams SB; Kacker R; Steele GS; Richie JP
    Urol Oncol; 2012; 30(1):60-3. PubMed ID: 20189842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resection of postchemotherapy residual masses and limited retroperitoneal lymphadenectomy in patients with metastatic testicular nonseminomatous germ cell tumors.
    Aprikian AG; Herr HW; Bajorin DF; Bosl GJ
    Cancer; 1994 Aug; 74(4):1329-34. PubMed ID: 8055456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Value of Teratoma in Primary Tumor and Postchemotherapy Retroperitoneal Lymph Node Dissection Specimens in Patients With Metastatic Germ Cell Tumor.
    Taza F; Chovanec M; Snavely A; Hanna NH; Cary C; Masterson TA; Foster RS; Einhorn LH; Albany C; Adra N
    J Clin Oncol; 2020 Apr; 38(12):1338-1345. PubMed ID: 32134699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Teratoma in primary testis tumor reduces complete response rates in the retroperitoneum after primary chemotherapy. The case for primary retroperitoneal lymph node dissection of stage IIb germ cell tumors with teratomatous elements.
    Rabbani F; Gleave ME; Coppin CM; Murray N; Sullivan LD
    Cancer; 1996 Aug; 78(3):480-6. PubMed ID: 8697394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical impact of residual extraretroperitoneal masses in patients with advanced nonseminomatous germ cell testicular cancer.
    Masterson TA; Shayegan B; Carver BS; Bajorin DF; Feldman DR; Motzer RJ; Bosl GJ; Sheinfeld J
    Urology; 2012 Jan; 79(1):156-9. PubMed ID: 22202548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma.
    Carver BS; Shayegan B; Serio A; Motzer RJ; Bosl GJ; Sheinfeld J
    J Clin Oncol; 2007 Mar; 25(9):1033-7. PubMed ID: 17261854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Long-term results of laparoscopic retroperitoneal lymph node dissection (RPLND) in low-stage nonseminomatous germ-cell testicular tumors (NSGCTT) performed by a senior surgeon: 1999-2003].
    Pizzocaro G; Schiavo M; Solima S; Vitellaro M; Biasoni N; Nicolai N
    Urologia; 2010; 77 Suppl 17():50-6. PubMed ID: 21308676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Teratoma in the orchiectomy specimen and volume of metastasis are predictors of retroperitoneal teratoma in post-chemotherapy nonseminomatous testis cancer.
    Beck SD; Foster RS; Bihrle R; Ulbright T; Koch MO; Wahle GR; Einhorn LH; Donohue JP
    J Urol; 2002 Oct; 168(4 Pt 1):1402-4. PubMed ID: 12352402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant surgery in testicular cancer patients undergoing postchemotherapy retroperitoneal lymph node dissection.
    Djaladat H; Nichols C; Daneshmand S
    Ann Surg Oncol; 2012 Jul; 19(7):2388-93. PubMed ID: 22395993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Practice Patterns and Impact of Postchemotherapy Retroperitoneal Lymph Node Dissection on Testicular Cancer Outcomes.
    Woldu SL; Moore JA; Ci B; Freifeld Y; Clinton TN; Aydin AM; Singla N; Laura-Maria K; Hutchinson RC; Amatruda JF; Sagalowsky A; Lotan Y; Arriaga Y; Margulis V; Xie Y; Bagrodia A
    Eur Urol Oncol; 2018 Aug; 1(3):242-251. PubMed ID: 31058267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blood testis barrier revisited-Analysis of post-chemotherapy germ cell tumor orchidectomy and retroperitoneal lymph node dissection specimens.
    Gupta A; Noronha J; Bakshi G; Menon S; Pal M; Joshi A; Prabash K; Noronha V; Murthy V; Krishnattry R; Patil A; Prakash GJ
    J Surg Oncol; 2021 Mar; 123(4):1157-1163. PubMed ID: 33428791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative Effectiveness of Risk-adapted Surveillance vs Retroperitoneal Lymph Node Dissection in Clinical Stage I Nonseminomatous Germ Cell Testicular Cancer: A Retrospective Follow-up Study of 81 Patients.
    Fan G; Zhang L; Yi L; Jiang ZQ; Ke Y; Wang XS; Xiong YY; Han WQ; Zhou X; Liu C; Yu X
    Asian Pac J Cancer Prev; 2015; 16(8):3267-72. PubMed ID: 25921130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Percentage of Teratoma in Orchiectomy and Risk of Retroperitoneal Teratoma at the Time of Postchemotherapy Retroperitoneal Lymph Node Dissection in Germ Cell Tumors.
    Calaway AC; Kern SQ; Crook D; Tong Y; Masterson TA; Adra N; Einhorn LH; Foster RS; Cary C
    J Urol; 2021 Dec; 206(6):1430-1437. PubMed ID: 34288715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.